Health Affairs' Rob Lott interviews Michael T. Osterholm, the director of the Center for Infectious Disease Research and ...

If we are serious about narrowing health gaps, then our environmental protections must be safeguarded against political ...

We must resist the temptation to reinterpret the Bayh-Dole Act even in an effort to improve the affordability of and access ...

In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...

Valerie Lehman is an Assistant Research Director on the Health Care Transformation team at the Duke-Margolis Institute for Health Policy and manages the rapid lear ...

Prior authorization is a barrier to accessing medications for opioid use disorder (MOUD). Although private insurance covered about one-third of patients with OUD in 2023, the understanding of prior ...

Under the Consolidated Appropriations Act, 2023, which required the provision of national twelve-month continuous Medicaid eligibility for children up to age nineteen, children’s Medicaid enrollment ...

Without policy intervention to address average sales price-based challenges to biosimilar market sustainability, there is a ...

US v. Skrmetti undermined constitutional guardrails that guarantee rigorous assessment of medical justifications for policies limiting the rights of transgender people and women, creating a need and ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of ...

While recent fertility drug-related announcements by the Trump administration could result in savings for women—especially ...